SCHEMBL2223205

SCHEMBL2223205

CCOC(=O)C(CCC(=O)O)C(C#N)CC(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.37
GABRD O14764 2/20 0.37
GABRA1 P14867 2/20 0.37
GABRB1 P18505 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
GABRB2 P47870 2/20 0.37
GABRA4 P48169 2/20 0.37
GABRE P78334 2/20 0.37
GABRA6 Q16445 2/20 0.37
GABRG1 Q8N1C3 2/20 0.37
GABRG3 Q99928 2/20 0.37
GABRQ Q9UN88 2/20 0.37
FOLH1 Q04609 9/20 0.35
PLA2G10 O15496 2/20 0.34
CYP1A2 P05177 1/20 0.33
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18548797 0.95 GABRP (0.33) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7343378 0.83 FOLH1 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL28304232 0.83 FOLH1 (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL268072 0.83 MEN1 (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL268058 0.83 MEN1 (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL268067 0.83 MEN1 (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL31164267 0.83 MEN1 (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL28949225 0.78 FOLH1 (0.35) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL261164 0.76 LMNA (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2
SCHEMBL2637205 0.76 LMNA (0.37) ALDH1A1MEN1GAAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117802069-B Du Bangshi thermomyces lipase mutant, coding gene, engineering bacterium and application thereof 新余学院 2025-01-28 CN claimed
CN-117802069-A Du Bangshi thermomyces lipase mutant, coding gene, engineering bacterium and application thereof 新余学院 2024-04-02 CN claimed
CN-106676084-B A kind of lipase mutant, encoding gene and its application from thermophilic ankle section bacterium 浙江工业大学 2019-11-29 CN claimed
CN-106591258-B A kind of lipase gene, carrier, engineering bacteria and its application 新余学院 2019-06-04 CN claimed
CN-121874156-A Lipase mutant and application thereof 青岛蔚蓝生物集团有限公司 2026-04-17 CN disclosed
CN-121874157-A Lipase mutant 青岛蔚蓝生物集团有限公司 2026-04-17 CN disclosed
CN-120082537-B Lipase mutant 青岛蔚蓝生物集团有限公司 2026-03-17 CN disclosed
CN-120082537-A Lipase mutant 青岛蔚蓝生物集团有限公司 2025-06-03 CN disclosed
US-20250084395-A1 ENGINEERED NITRILASES FOR BIOCATALYSIS KCAT ENZYMATIC PRIVATE LIMITED (IN) 2025-03-13 US disclosed
CN-117802069-B Du Bangshi thermomyces lipase mutant, coding gene, engineering bacterium and application thereof 新余学院 2025-01-28 CN disclosed
CN-117802069-B Du Bangshi thermomyces lipase mutant, coding gene, engineering bacterium and application thereof 新余学院 2025-01-28 CN disclosed
CN-117802069-A Du Bangshi thermomyces lipase mutant, coding gene, engineering bacterium and application thereof 新余学院 2024-04-02 CN disclosed
WO-2009044409-A2 NOVEL RESOLUTION PROCESS FOR PREGABALIN NATCO PHARMA LIMITED (IN) 2009-04-09 WO disclosed
EP-1912931-A2 PREPARATION OF (S)-PREGABALIN-NITRILE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-04-23 EP disclosed
EP-1913147-A2 THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN Teva Pharmaceutical Industries Ltd (IL) 2008-04-23 EP disclosed
US-20080026433-A1 Use of enzymatic resolution for the preparation of intermediates of pregabalin TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-01-31 US disclosed
US-20080015385-A1 Preparation of (S)-pregabalin-nitrile TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-01-17 US disclosed
WO-2007143152-A2 PREPARATION OF (S)-PREGABALIN-NITRILE TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-12-13 WO disclosed
WO-2007143113-A2 THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2007-12-13 WO disclosed
US-20060270871-A1 POLYMORPHIC FORM I OF PREGABALIN AND PROCESSES FOR ITS PREPARATION RANBAXY LABORATORIES LIMITED (IN) 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015385-A1 Preparation of (S)-pregabalin-nitrile GABRE, GAP43, RIMKLA GABRP 11/4885GABRD 9/4885GABRA1 21/4885
US-20060270871-A1 POLYMORPHIC FORM I OF PREGABALIN AND PROCESSES FOR ITS PREPARATION GABRP, GABRB1, GABRB2 GABRP 1/4885GABRD 14/4885GABRA1 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.